This inventor holds 1 USPTO granted patent. Top assignees: Fondazione Telethon, Ospedale San Raffaele S.r.l., The Board of Trustees of the Leland Stanford Rinior University. Active years: 2026.
Company Filing History:
1 out of 40 
1 out of 55 
1 out of 1 Years Active: 2026
Title: Laura Passerini: Innovator in Immunotherapy
Introduction
Laura Passerini is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of immunotherapy, particularly through her innovative work on engineered T cells. Her research focuses on promoting immune tolerance, which is crucial for advancing therapeutic strategies in various medical conditions.
Latest Patents
Laura Passerini holds a patent for "FOXP3 engineered CD4+ T cells for use in treg-based immunotherapy." This patent describes engineered Treg-like cells, specifically CD4T cells, and their application in cellular therapy to enhance immune tolerance. The process involves transducing CD4T cells with a lentiviral vector that expresses FOXP3 under a constitutive promoter. The transduced cells exhibit high and persistent levels of FOXP3 expression and acquire immune suppressive characteristics similar to naturally occurring Treg cells.
Career Highlights
Throughout her career, Laura has worked with esteemed institutions, including the Board of Trustees of the Leland Stanford Junior University and Ospedale San Raffaele S.r.l. Her research has significantly impacted the understanding and application of T cell engineering in immunotherapy.
Collaborations
Laura has collaborated with notable colleagues in her field, including Rosa Bacchetta and Maria Grazia Roncarolo. Their joint efforts have furthered advancements in cellular therapies and immune tolerance.
Conclusion
Laura Passerini's innovative work in engineered T cells and immunotherapy exemplifies her commitment to advancing medical science. Her contributions are paving the way for new therapeutic approaches that could transform patient care.